HomeFull speed ahead. Keep track of advancements in every frontier

TheTechno Optimist.

Hepatocyte epigenetic reprogrammingNewLimit—Hepatocyte epigenetic reprogrammingNewLimit—Hepatocyte epigenetic reprogrammingNewLimit—Hepatocyte epigenetic reprogrammingNewLimit—T cell rejuvenationNewLimit—

T cell rejuvenation

by NewLimitUS

ResearchStage 1 of 5

Early discovery: same screening method applied to old immune T cells.

Updated 27 Mar 2026Checked 25 Sep0 updates this week

Milestones

Next · Pick lead candidate
  1. T cell program announced2024Complete.
  2. Pick lead candidateNowCurrent milestone.

Most important updates

  • 27 Mar 2026
  • 30 Sep 2025
  • 23 Jun 2025
  • 14 Mar 2025

Physics limits

  • The thymus shrinks and fixing T cells can't regrow itNew T cells are trained in the thymus, which shrinks steadily from puberty. Rejuvenating the T cells that remain can't restore the variety of targets lost as fewer new ones are made.
  • T cells are hard to reach in the bodyT cells circulate through blood and lymph nodes. Carriers that deliver genes to them in the body, without the liver soaking up most of the dose, are still early.
  • Stronger immunity can turn on the bodyImmune cells that are too active attack healthy tissue. Any boost has to stay below the level that causes autoimmunity or runaway inflammation.

How it works

3 parts
A human T cell under a scanning electron microscope: the kind of immune cell NewLimit tries to make young again
A human T cell under a scanning electron microscope: the kind of immune cell NewLimit tries to make young againPhoto: NIAID · CC BY 2.0 (opens commons.wikimedia.org)
Screen

Test gene-switch sets in old T cells

Pools of old human T cells each get a different set of transcription factors, the master switches that turn groups of genes on.

Score

Pick sets that restore function

Winners make old T cells multiply, fight and regulate like young ones, not just look young in their gene activity.

Learn

AI suggests the next round

Models trained on each screen predict new combinations to test, so each cycle searches fewer dead ends.

Update log

4 updates

Fri 27 Mar

  • Minor: BlogResearch

Tue 30 Sep 2025

  • Minor: BlogResearch

Mon 23 Jun 2025

  • Minor: BlogResearch

Fri 14 Mar 2025

  • Minor: BlogResearch

About NewLimit

The team behind T cell rejuvenation

NewLimit

Reprogramming, liver, AI screening

San Francisco company co-founded in 2021 by Coinbase CEO Brian Armstrong and Blake Byers, with scientists Jacob Kimmel and Greg Johnson. It uses big lab screens and AI to find gene switches that make old cells work like young ones. First target: the liver.

  • Raised $435M led by Founders Fund at a $3.1B valuation in Jun 2026, about triple its 2025 value.
  • Says its prototype made old human liver cells look younger on four measures, after testing over 3,000 gene-switch combinations.
  • Plans a first human trial of its liver treatment; timing is a company target.

newlimit.com (opens newlimit.com)Company profile →

Founded
20215 yrs
Headquarters
United States
Status
Private
Valuation
$3.1BprivateJun 2026
Raised
$610M3 rounds
Last round
Series C · $435MJun 2026$3.1B post
Works in
LongevityCellular reprogrammingAI
Coverage
2 programs · 12 updateslatest 10 Jul 2026checked 25 Sep
Lead investors
Founders FundKleiner Perkins
Investors
Founders Fund (opens foundersfund.com)Kleiner Perkins (opens kleinerperkins.com)Eli Lilly
People
Brian Armstrong (opens en.wikipedia.org)Co-founderBlake ByersCo-founderJacob KimmelCo-founder and head of research
Primer